Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc

Mar 14 • 04:00PM ET

111.44

Dollar change -1.91
Percentage change -1.69	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB COWZ VYM

Scroll to Statements

Index	NDX, S&P 500	P/E	303.57	EPS (ttm)	0.37	Insider Own	0.19%	Shs Outstand	1.25B	Perf Week	-5.08%
Market Cap	138.78B	Forward P/E	13.21	EPS next Y	8.44	Insider Trans	-24.40%	Shs Float	1.24B	Perf Month	7.87%
Income	480.00M	PEG	12.27	EPS next Q	1.77	Inst Own	86.59%	Short Float	1.82%	Perf Quarter	20.68%
Sales	28.73B	P/S	4.83	EPS this Y	72.25%	Inst Trans	1.34%	Short Ratio	2.86	Perf Half Y	37.68%
Book/sh	15.51	P/B	7.18	EPS next Y	6.04%	ROA	0.79%	Short Interest	22.58M	Perf Year	48.43%
Cash/sh	9.29	P/C	12.00	EPS next 5Y	24.75%	ROE	2.28%	52W Range	62.07 - 119.96	Perf YTD	20.65%
Dividend Est.	3.10 (2.78%)	P/FCF	13.47	EPS past 5Y	-38.13%	ROI	1.07%	52W High	-7.10%	Beta	0.33
Dividend TTM	3.87 (3.47%)	Quick Ratio	1.45	Sales past 5Y	5.30%	Gross Margin	78.24%	52W Low	79.54%	ATR (14)	2.65
Dividend Ex-Date	Mar 14, 2025	Current Ratio	1.60	EPS Y/Y TTM	-91.54%	Oper. Margin	37.11%	RSI (14)	56.00	Volatility	2.38% 2.37%
Employees	17600	Debt/Eq	1.41	Sales Y/Y TTM	6.16%	Profit Margin	1.67%	Recom	1.81	Target Price	113.09
Option/Short	Yes / Yes	LT Debt/Eq	1.31	EPS Q/Q	24.48%	Payout	805.23%	Rel Volume	1.09	Prev Close	113.35
Sales Surprise	5.82%	EPS Surprise	9.35%	Sales Q/Q	6.39%	Earnings	Feb 11 AMC	Avg Volume	7.90M	Price	111.44
SMA20	-0.78%	SMA50	9.65%	SMA200	29.98%	Trades		Volume	8,644,625	Change	-1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100

Show Previous Ratings

Mar-14-25 02:34PM	Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly (CNBC TV)
09:55AM	Gilead Sciences - Women's History Month Celebrated With Its Team (ACCESSWIRE)
Mar-13-25 01:07PM	Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds (Insider Monkey)
11:30AM	Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
02:16PM	Loading…
Mar-12-25 02:16PM	Analyst Says Gilead Sciences (GILD) is a Big Liquid Stock You Should Pay Attention To (Insider Monkey)
12:55PM	Gilead Presents New HIV Treatment And Cure Research Data (Benzinga)
08:30AM	Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option (Business Wire)
08:23AM	Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success (Clinical Trials Arena)
08:15AM	A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV (BioPharma Dive)
Mar-11-25 01:37PM	First Clinical Data for Gileads Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet (Business Wire)
05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory)
04:20AM	The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) (Motley Fool)
Mar-10-25 09:40AM	Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:01AM	1 Value Stock with Exciting Potential and 2 to Ignore (StockStory)
11:21AM	Loading…
Mar-08-25 11:21AM	CDC plans study into potential vaccines, autism connections, Reuters reports (TipRanks)
03:53AM	Buy Gilead Sciences (GILD) Stock at 52-Week Highs? (Zacks)
Mar-05-25 03:39PM	Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out (Barrons.com)
01:31PM	5 Big Biopharmaceutical Stocks That Are Finding Favor (Barrons.com)
09:15AM	Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-03-25 05:50PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Feb-28-25 09:30AM	Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy? (Zacks)
07:00AM	Drug Stocks Are the New Safe Bet in a Shaky Market (The Wall Street Journal)
Feb-27-25 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
07:09AM	Patient Insight Institute announces partnership to improve cancer screening (Hospital Management)
Feb-25-25 11:21AM	Morgan Stanley sees FDA approval of GILD's Lenacapavir (Investing.com)
07:05AM	Gileads lenacapavir applications for HIV gain EMA validation (Pharmaceutical Technology)
Feb-24-25 08:30AM	European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention (Business Wire)
Feb-23-25 01:14PM	Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolios Top Stock Picks (Insider Monkey)
Feb-21-25 12:14PM	Gileads lenacapavir under priority review could revolutionise HIV PrEP (Clinical Trials Arena)
05:00AM	Loading…
05:00AM	Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup (Quartz)
Feb-20-25 04:30PM	Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis (Business Wire)
11:25AM	Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up (Insider Monkey)
09:40AM	Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	How To Trade Stocks: Do You Know The Seven Most Important Words On Wall Street? (Investor's Business Daily)
Feb-19-25 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
11:05AM	The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease (ACCESSWIRE)
06:58AM	Sanofi reaches consumer health deal; Supernus antidepressant fails study (BioPharma Dive)
Feb-18-25 02:07PM	Gileads lenacapavir moves closer to FDA approval for HIV PrEP use (Pharmaceutical Technology)
01:23PM	Calls of the Day: Gilead Sciences and Merck (CNBC TV)
12:59PM	A new HIV prevention drug could get FDA approval this year (Quartz)
12:36PM	Deutsche Bank upgrades Gilead on its HIV treatment franchise (Investing.com)
08:30AM	U.S. FDA Accepts Gileads New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review (Business Wire)
Feb-17-25 09:15AM	Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue? (Zacks)
07:57AM	Gilead Sciences, Inc. (GILD): A Bull Case Theory (Insider Monkey)
Feb-13-25 09:50AM	Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Feb-12-25 04:36PM	S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth (Investopedia) +7.46%
04:18PM	Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
01:49PM	Why Gilead Sciences (GILD) Stock Is Trading Up Today (StockStory)
12:21PM	Why Gilead Sciences Stock Is Jumping Today (Motley Fool)
10:53AM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
10:44AM	Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
09:40AM	Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
07:50AM	Q4 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ... (GuruFocus.com)
Feb-11-25 10:15PM	Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript (Motley Fool)
07:30PM	Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates (Zacks)
05:05PM	Zillow, Gilead Sciences, Freshworks: After-Hours Earnings (Yahoo Finance Video)
04:31PM	Gilead Soars Into Buy Zone After Obliterating Fourth-Quarter Expectations (Investor's Business Daily)
04:14PM	Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers (StockStory)
04:10PM	Gileads Profit View Tops Estimates After Strong End to Year (Bloomberg)
04:08PM	Gilead: Q4 Earnings Snapshot (Associated Press Finance)
04:08PM	Gilead provides upbeat 2025 forecast, shares rise 4% (Reuters)
04:08PM	Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising. (Barrons.com)
04:07PM	Gilead Outplays Veklury Downfall To Obliterate Forecasts. Will Shares Win Back Their Breakout? (Investor's Business Daily)
04:05PM	Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend (Business Wire)
04:02PM	Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
05:30AM	The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings. (The Wall Street Journal)
Feb-10-25 07:00PM	Coca-Cola results, Powell testifies, SMCI update: What to Watch (Yahoo Finance Video)
08:04AM	Gilead Sciences (GILD) Q4 Earnings: What To Expect (StockStory)
Feb-09-25 02:30PM	3 Fabulous Dividend Stocks to Buy in February (Motley Fool)
Feb-08-25 08:30AM	These 2 Dividend Stocks Are Absolute Bargains Right Now (Motley Fool)
Feb-06-25 09:45AM	3 Top AI-Powered Biotech Stocks to Buy in February (Motley Fool)
09:15AM	Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-05-25 05:50PM	Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
11:54AM	Is Gilead Sciences (GILD) the Best Wide Moat Stock to Invest In? (Insider Monkey)
Feb-04-25 10:00AM	Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-03-25 06:00PM	Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts (Zacks)
Jan-31-25 12:10PM	Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:47AM	Top 20 biopharma companies market caps rise 1.7% over 2024 amid policy (Pharmaceutical Technology)
07:09AM	Gilead Sciences, Inc. (GILD): AI Partnerships Enhancing Biopharmaceutical Advancements (Insider Monkey)
Jan-30-25 08:00AM	Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications (PR Newswire)
Jan-29-25 09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
Jan-28-25 06:00PM	Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts (Zacks)
04:05PM	Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)
09:30AM	Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? (Zacks)
Jan-24-25 04:31PM	Why Gilead Sciences (GILD) Is One of the Best Humane Stocks to Invest in Now? (Insider Monkey)
Jan-21-25 06:00PM	Why Gilead Sciences (GILD) Outpaced the Stock Market Today (Zacks)
05:30PM	Is Gilead Sciences (GILD) Among Billionaire Steve Cohens Top Stock Picks? (Insider Monkey)
Jan-17-25 03:25PM	House of the Week: A Riverfront Retreat in Southeastern Connecticut (The Wall Street Journal)
Jan-16-25 01:12PM	Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? (Insider Monkey)
09:00AM	Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? (Zacks)
Jan-15-25 06:00PM	Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
03:44PM	Gilead Sciences, US government settle patent case over HIV prevention drugs (Reuters)
Jan-13-25 02:44PM	Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies (GuruFocus.com)
10:49AM	Gilead and LEO Pharma link on programmes for inflammatory conditions (Pharmaceutical Technology)
Jan-11-25 12:39PM	Gilead, LEO Pharma partner to develop programs for inflammatory diseases (Reuters)
11:00AM	Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases (Business Wire)
Jan-10-25 10:48AM	Morgan Stanley upgrades Gilead on HIV treatment growth (Investing.com)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Option Exercise	63.91	17,929	1,145,842	186,990	Mar 12 06:41 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Sale	118.17	17,929	2,118,696	169,061	Mar 12 06:41 PM
ANDREW DICKINSON	Officer	Mar 10 '25	Proposed Sale	118.17	17,929	2,118,695		Mar 10 04:02 PM
MERDAD V PARSEY	Officer	Mar 03 '25	Proposed Sale	115.70	21,910	2,534,913		Mar 03 04:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Dickinson Andrew D	Chief Financial Officer	Feb 18 '25	Sale	104.09	2,500	260,225	169,061	Feb 19 04:43 PM
ANDREW DICKINSON	Officer	Feb 18 '25	Proposed Sale	104.09	2,500	260,225		Feb 18 04:14 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Option Exercise	67.27	137,676	9,260,873	308,899	Feb 13 09:13 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Sale	102.22	137,676	14,073,241	171,223	Feb 13 09:13 PM
ANDREW DICKINSON	Officer	Feb 12 '25	Proposed Sale	102.22	137,676	14,073,241		Feb 12 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Option Exercise	67.52	142,180	9,600,576	273,053	Feb 03 06:09 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Sale	97.22	142,180	13,822,740	129,873	Feb 03 06:09 PM
ANDREW DICKINSON	Officer	Jan 31 '25	Proposed Sale	97.22	142,180	13,822,740		Jan 31 04:15 PM
MERDAD V PARSEY	Officer	Jan 31 '25	Proposed Sale	98.00	184,683	18,098,989		Jan 31 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '25	Sale	91.35	2,500	228,375	129,873	Jan 16 03:31 PM
ANDREW DICKINSON	Officer	Jan 15 '25	Proposed Sale	91.35	2,500	228,375		Jan 15 04:18 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM
Parsey Merdad	Chief Medical Officer	Oct 01 '24	Sale	83.83	2,000	167,660	100,189	Oct 02 04:58 PM
MERDAD V PARSEY	Officer	Oct 01 '24	Proposed Sale	83.83	2,000	167,660		Oct 01 04:27 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Option Exercise	57.92	25,000	1,448,000	123,435	Sep 13 07:07 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '24	Sale	84.50	21,246	1,795,287	102,189	Sep 13 07:07 PM
Mercier Johanna	Chief Commercial Officer	Sep 12 '24	Sale	83.78	29,357	2,459,577	78,127	Sep 13 05:08 PM
MERDAD V PARSEY	Officer	Sep 12 '24	Proposed Sale	84.50	21,246	1,795,287		Sep 12 04:45 PM
JOHANNA MERCIER	Officer	Sep 12 '24	Proposed Sale	83.78	29,357	2,459,577		Sep 12 04:43 PM
Mercier Johanna	Chief Commercial Officer	Aug 28 '24	Sale	78.03	9,513	742,299	105,466	Aug 29 03:23 PM
JOHANNA MERCIER	Officer	Aug 28 '24	Proposed Sale	78.03	9,513	742,299		Aug 28 04:18 PM
Mercier Johanna	Chief Commercial Officer	Aug 13 '24	Sale	73.98	5,490	406,150	114,979	Aug 14 02:23 PM
JOHANNA MERCIER	Officer	Aug 13 '24	Proposed Sale	73.98	5,490	406,150		Aug 13 04:27 PM
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380	Jul 01 08:06 PM
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience